Skip to content

Head to head

GIP against Tirzepatide

The native hormone against the drug that added its receptor to a GLP-1 backbone. What GIP receptor activity contributes on its own is still argued about, including whether agonism or antagonism is the useful direction, which is why MariTide blocks the same receptor tirzepatide activates.

Column A

GIP

Glucose-dependent insulinotropic polypeptide

One of your two incretin hormones, and the parent ligand of every dual and triple agonist on this site. Both blocking it and activating it produce weight loss in humans, which nobody has resolved.

Column B

Tirzepatide

Tirzepatide (dual GIP/GLP-1 receptor agonist)

A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.

Side by side, on the facts we can check

AttributeGIPTirzepatide
CategoryMetabolicMetabolic
FDA statusNot an approved drug and not in clinical use as a therapeutic. Drugs acting at its receptor are approved, including tirzepatide.FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea)
Half-lifeShort. Inactivated by dipeptidyl peptidase-4. No single agreed numeric half-life for intact human GIP resolved in our sources, so none is asserted here.~5 days
Molecular weightMature peptide is 42 amino acids (residues 52 to 93 of the 153-residue precursor, UniProt P09681). The precursor is 17,108 Da; we do not assert a mature-peptide mass because no source we loaded states one.4,813.5 Da
MechanismBinds GIPR, a class B1 secretin-family G protein-coupled receptor that is canonically Gs-coupled and raises cAMP. In the pancreatic beta cell that potentiates glucose-stimulated insulin secretion, which is glucose-dependent, so GIP does not drive insulin release when glucose is normal. GIPR is also expressed in adipose tissue, bone and the central nervous system, and the non-pancreatic actions are where most of the recent human work sits. GIP is inactivated by dipeptidyl peptidase-4, which is the same enzyme the DPP-4 inhibitor drugs block.Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects.
Human studies cited64
Legal status, USNot a drug; endogenous hormone and research infusion peptideFDA-approved, prescription only
open the GIP profileopen the Tirzepatide profile

Frequently asked questions

What is the difference between GIP and Tirzepatide?

GIP: One of your two incretin hormones, and the parent ligand of every dual and triple agonist on this site. Both blocking it and activating it produce weight loss in humans, which nobody has resolved. Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.

Which has stronger research evidence, GIP or Tirzepatide?

This database does not grade compounds. It counts what was run in people: 6 of the 7 studies cited on the GIP profile were human work, against 4 of 4 for Tirzepatide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.

Are GIP and Tirzepatide FDA-approved?

GIP: Not an approved drug and not in clinical use as a therapeutic. Drugs acting at its receptor are approved, including tirzepatide.. Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea).

Related posts

Blog articles that cover GIP or Tirzepatide, newest first.

Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.